Actively Recruiting
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
Led by West China Second University Hospital · Updated on 2023-12-27
35
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ovarian cancer, and an elevated CA125 indicates a later stage and a worse prognosis. However about 20% of patients with ovarian cancer have low CA125 expression. Therefore, CA125 is not sensitive to some ovarian cancers with a high risk of recurrence. How to improve the diagnostic performance of these CA125-insensitive patients is a difficult problem in current research. Minimal residual disease (MRD) refers to the residual tumor components in the body of tumor patients after achieving complete remission through treatment. MRD detection is mainly achieved by liquid biopsy, and residual tumor components can be detected by circulating tumor DNA (ctDNA). This study aims to explore the value of MRD (ctDNA) in the risk assessment of CA125 non sensitive ovarian cancer populations by combining ctDNA with traditional imaging and serological tumor markers.
CONDITIONS
Official Title
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75
- Pathologically confirmed ovarian cancer
- CA125 200U/ml at first diagnosis or recurrence
- Physical condition score PS 2 points
- Enough tumor samples available for whole exome sequencing detection
- Patients and families understand the study and provide written informed consent
You will not qualify if you...
- Unable to provide sufficient tissue or blood samples for research detection
- Pregnant or lactating women
- Other diseases that may affect prognosis and survival as judged by the research doctor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
west china second University， SICHUAN University, China
Chengdu, Sichuan, China, 610016
Actively Recruiting
Research Team
R
Rutie Yin
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here